Overview

Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the combination of ABI-007 with gemcitabine or with LV5FU2.
Phase:
Phase 2
Details
Lead Sponsor:
GERCOR - Multidisciplinary Oncology Cooperative Group
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Collaborator:
Celgene Corporation
Treatments:
Albumin-Bound Paclitaxel
Fluorouracil
Gemcitabine
Paclitaxel